Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

Mohammed Alcharakh, Seongseok Yun, Yimin Dong, Nicole D. Vincelette, Madiha Daud, Saima Manzoor, Irbaz Bin Riaz, Faiz - Anwer

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

Original languageEnglish (US)
Pages (from-to)847-852
Number of pages6
JournalImmunotherapy
Volume8
Issue number8
DOIs
StatePublished - Jul 1 2016

Keywords

  • Biphenotypic acute leukemia
  • blinatumomab
  • CD19

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia'. Together they form a unique fingerprint.

  • Cite this